Activated Histone Acetyltransferase p300/CBP-Related Signalling Pathways Mediate Up-Regulation of NADPH Oxidase,

Alexandra-Gela Lazar1, Mihaela-Loredana Vlad1, Adrian Manea1

  • 1Institute of Cellular Biology and Pathology, "Nicolae Simionescu" of the Romanian Academy, 050568 Bucharest, Romania.

Insights

Histone acetyltransferase p300/CBP inhibitors reduce kidney damage in diabetic mice by decreasing inflammation and oxidative stress. This suggests p300/CBP inhibitors may treat diabetic kidney disease.

Area of Science:

  • Epigenetics
  • Nephrology
  • Diabetology

Background:

  • Epigenetic mechanisms, specifically histone acetylation, are implicated in diabetic complications.
  • Diabetic kidney disease (DKD) is a chronic inflammatory condition leading to kidney failure.
  • The role of histone acetyltransferase p300/CBP in diabetes-accelerated kidney damage is under investigation.

Purpose of the Study:

  • To investigate the role of p300/CBP in regulating renal NADPH oxidase (Nox), reactive oxygen species (ROS) production, inflammation, and fibrosis in diabetic mice.
  • To assess the therapeutic potential of p300/CBP inhibition in mitigating DKD.

Main Methods:

  • Diabetic C57BL/6J mice were treated with a selective p300/CBP inhibitor (C646) or vehicle for 4 weeks.
  • Kidney tissues were analyzed for levels of histone acetylation marks (H3K27ac), Nox subtypes, pro-inflammatory and pro-fibrotic molecules, and ROS production.

Main Results:

  • C646 treatment significantly reduced H3K27ac levels in the kidneys of diabetic mice.
  • Pharmacological inhibition of p300/CBP down-regulated diabetes-induced expression of Nox subtypes, inflammatory and fibrotic molecules.
  • Glomerular ROS overproduction was significantly reduced by C646 treatment.

Conclusions:

  • p300/CBP activation contributes to ROS production, inflammation, and fibrosis in the diabetic kidney.
  • Inhibition of p300/CBP effectively modulates diabetes-associated pathological processes.
  • p300/CBP inhibitors show promise as a therapeutic strategy for reducing the burden of DKD.